Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dimefline is a small molecule respiratory stimulant belonging to the class of 7-O-methylated flavonoids. It has been primarily used for the treatment of respiratory insufficiency and related conditions such as chronic obstructive pulmonary disease (COPD), bronchial asthma, and pulmonary emphysema. Dimefline acts by stimulating both peripheral chemoreceptors and central respiratory centers, leading to increased depth and efficiency of respiration without significantly increasing the rate. Its mechanism involves antagonism of gamma-aminobutyric acid (GABA) receptors in the central nervous system, which increases neuronal excitability and enhances phrenic nerve discharges that control diaphragm movement. The drug has a brief duration of action and is contraindicated in patients with epilepsy or severe neurological conditions[1][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dimefline.